PETQ PetIQ Inc. Class A

PetIQ, Inc. Announces Appointment of Lauren Olavessen, DVM as Chief Medical Officer

PetIQ, Inc. Announces Appointment of Lauren Olavessen, DVM as Chief Medical Officer

EAGLE, Idaho, Feb. 03, 2020 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced the appointment of Lauren Olavessen, DVM to the Company’s newly established position of senior vice president and chief medical officer, effective today. Dr. Olavessen has held a variety of medical and leadership roles at both Merial (now Boehringer Ingelheim) and IDEXX Laboratories, culminating in her post as senior medical director of IDEXX’s Companion Animal Medical Organization. 

“We are thrilled to welcome Lauren to our management team and leverage her well-rounded skill set of medical and leadership experience that she developed at two of the leading animal health companies in the world,” commented Susan Sholtis, PetIQ’s President. “PetIQ’s business has expanded significantly and today represents one of the leading veterinary service providers and vertically integrated product manufacturers in the industry. Lauren’s cross-functional experience will be of great value to our team as we further expand our presence in the industry and advance our growth initiatives to bring Smarter Pet Health to the unserved and underserved segments of the pet population.”

Dr. Olavessen brings 18 years of experience in the veterinary profession, both as a practicing veterinarian and a leader within the industry. Most recently, she served as senior medical director of IDEXX’s Companion Animal Medical Organization where she led a team of veterinarians and professionals in medical affairs, medical outreach and medical research support. She began her career as a practicing veterinarian focused on small animal medicine in 2002 until transitioning to industry in 2007. Dr. Olavessen holds a Doctorate of Veterinary Medicine from the University of Tennessee College of Veterinary Medicine, serves on the board of directors for the Veterinary Leadership Institute (VLI) and has been recognized with several educational and professional awards. 

About PetIQ

PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded distributed medications, which is further supported by its own world-class medications manufacturing facility in Omaha, Nebraska. The company’s national service platform, VIP Petcare, operates in over 3,400 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them. For more information, visit .

Contacts:

Investor Relations Contact:

ICR

Jeff Sonnek

646-277-1263

Media Relations Contact:

ICR

Cory Ziskind

646-277-1232

EN
03/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PetIQ Inc. Class A

 PRESS RELEASE

PetIQ Names Camillo Pane as Chief Executive Officer

PetIQ Names Camillo Pane as Chief Executive Officer Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane’s passion for making a difference in the lives of consumers has been a constant focus through...

 PRESS RELEASE

PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Gr...

PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the tran...

 PRESS RELEASE

PetIQ, Inc. Announces Results of Special Meeting of Stockholders

PetIQ, Inc. Announces Results of Special Meeting of Stockholders Reports Merger Agreement with Bansk Group Approved by Stockholders and Anticipates a Closing Date of October 25, 2024 EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the “Agreement”) pursuant to which Bansk Group will acquir...

 PRESS RELEASE

PetIQ, Inc. Reports Second Quarter 2024 Financial Results

PetIQ, Inc. Reports Second Quarter 2024 Financial Results Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ’s Founder and CEO, commented, “We are ...

 PRESS RELEASE

PetIQ, Inc. Enters into Definitive Agreement to be Acquired by Bansk G...

PetIQ, Inc. Enters into Definitive Agreement to be Acquired by Bansk Group PetIQ Stockholders to Receive $31.00 Per Share in an All-Cash Transaction Valued at Approximately $1.5 Billion EAGLE, Idaho, and NEW YORK, New York, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, and Bansk Group (“Bansk”), a consumer-focused private investment firm dedicated to building distinctive consumer brands, today announced that PetIQ entered into a definitive agreement (the “Agreement”) pursuant to which Bansk...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch